

PRODUCT SPOTLIGHT

STABLE SIGNALS, STREAMLINED DISCOVERIES

ATCC reporter cell lines offer unparalleled precision and efficiency for basic research and biopharma scientists.

- By integrating bioluminescence reporters into biologically relevant tumor cell lines, ATCC provides robust tools for quantifiable, real-time monitoring of gene expression, cellular processes, and drug efficacy.
- Our highly authenticated tumor cell lines with added characterization facilitate high-throughput screening, in vivo imaging, and pathway analysis, significantly accelerating research timelines and enhancing the reliability of experimental outcomes.
- Versatile tools (various reporter formats; luciferase, GFP, dual GFP and luciferase, and inducible) for many scientific applications: Cancer research, stem cell studies, immuno-oncology therapeutic screening, and cell and gene therapy development.

EXPLORE OUR REPORTER CELLS ONLINE AT WWW.ATCC.ORG/REPORTERS

DUAL-LABELED REPORTER CELL LINES

ATCC now provides dual-labeled reporter cell lines that give you the dual advantages of both qualitative (visual) and quantitative (luminescent) data collection.

Designation	ATCC® No.	Disease	Notes	Function	Expression
4T1-GFP-Luc2	CRL-2539-GFP-LUC2™	Mimics human breast cancer; Stage IV	Tested in in vivo tumor study	Mouse syngeneic lines for in vivo studies	Constitutive
CT26.WT-GFP-Luc2	CRL-2638-GFP-LUC2™	Carcinoma	Tested in in vivo tumor study	Mouse syngeneic lines for in vivo studies	Constitutive
Raji-GFP-Luc2	CCL-86-GFP-LUC2™	Burkitt's Lymphoma	CAR-T Target: CD19	Human lines with endogenous CAR-Target	Constitutive
NCI-H929-GFP-Luc2	CRL-3580-GFP-LUC2™	Plasmacytoma	CAR-T Target: BCMA	Human lines with endogenous CAR-Target	Constitutive

CAR-TARGET REPORTERS

ATCC's credible tumor cell lines are available as luciferase reporters with additional characterization for the stable expression of emerging CAR-T target antigens.

Designation	ATCC® No.	Disease	Target	Expression
BT-474-Luc2	HTB-20-LUC2™	Breast Ductal Carcinoma	HER2	Constitutive
Daudi-Luc2	CCL-213-LUC2™	Burkitt's Lymphoma	CD20	Constitutive
Farage-Luc2	CRL-2630-LUC2™	Non-Hodgkin's B Cell Lymphoma	CD20	Constitutive
Raji-Luc2	CCL-86-LUC2™	Burkitt's Lymphoma	CD19	Constitutive
WIL2-S-Luc2	CRL-8885-LUC2™	B Cell Lymphoma	CD19	Constitutive

CHECKPOINT INHIBITOR REPORTERS

ATCC has a variety of inducible luciferase reporter cell lines for use in checkpoint immunotherapy screening and studying immunological responses in vitro and in vivo.

Designation	ATCC® No.	Disease	Validated endogenous checkpoint	Expression
BDCM NFκB-Luc2	CRL-2740-NFκB-LUC2™	Acute myelogenous leukemia	LILRB1, PD-L1, B7-1	Inducible
HCC827-GAS-Luc2	CRL-2868-GAS-LUC2™	Adenocarcinoma	PD-L1	Inducible
HMC3 NFκB-Luc2	CRL-3304-NFκB-LUC2™	Embryonic Microglia Clone 3	PD-L1, SIRPA	Inducible
KG-1 NFκB-Luc2	CCL-246-NFκB-LUC2™	Acute myelogenous leukemia	SIGLEC10	Inducible
MG-63-GAS-Luc2	CRL-1427-GAS-LUC2™	Osteosarcoma	CD-155	Inducible
MJ NFAT-LUC2	CRL-8294-NFAT-LUC2™	Cutaneous T Cell Lymphoma	TIGIT	Inducible
NCI-H1650-GAS-Luc2	CRL-5883-GAS-LUC2™	Adenocarcinoma	B7-H3	Inducible
SUP-T1 NFAT-Luc2	CRL-1942-NFAT-LUC2™	Lymphoblastic lymphoma	PD-1	Inducible
U-937 NFκB-Luc2	CRL-1593.2-NFκB-LUC2™	Histiocytic Lymphoma	SIRPA	Inducible

THP-1 REPORTERS

We provide a collection of THP-1 cells with inducible luciferase expression that can be used to study different immunological functions.

Designation	ATCC® No.	Disease	Signaling Pathway	Function	Expression
THP-1 AP1-LUC2	TIB-202-AP1-LUC2™	Acute monocytic leukemia	MAPK/ERK	Regulates innate and adaptive immune response	Inducible
THP-1 CRE-Luc2	TIB-202-CRE-LUC2™	Acute monocytic leukemia	cAMP/PKA	Inflammatory mediator and phagocytosis modulator	Inducible
THP-1 GAS-Luc2	TIB-202-GAS-LUC2™	Acute monocytic leukemia	JAK-STAT (Type II)	Initiates immune cell activation and recruitment	Inducible
THP-1 ISRE-Luc2	TIB-202-ISRE-LUC2™	Acute monocytic leukemia	JAK-STAT (Type I)	Initiates immune cell activation and recruitment	Inducible
THP-1 NFAT-Luc2	TIB-202-NFAT-LUC2™	Acute monocytic leukemia	Calcineurin-NFAT	Mediates adaptive T and B cell activation	Inducible
THP-1 NF-κB-Luc2	TIB-202-NFκB-LUC2™	Acute monocytic leukemia	NFκB	Pivotal mediator of inflammatory response	Inducible

EMT AND MET REPORTERS

ATCC provides fluorescently labeled cell lines for the study of epithelial to mesenchymal transition (EMT) and its reverse (MET), in vitro and in vivo.

Designation	ATCC® No.	Disease	Tissue	Expression
A-549 VIM RFP	CCL-185EMT™	Adenocarcinoma	Lung	inducible
BT-474 ECAD-EmGFP	HTB-20EMT™	Ductal carcinoma	Mammary	inducible
HCT116 VIM RFP	CCL-247EMT™	Carcinoma	Colon	inducible
MCF 10A Ecadherin EmGFP	CRL-10317EMT™	Fibrocystic disease	Mammary	inducible
MDA-MB-231 VIM RFP	HTB-26MET™	Adenocarcinoma	Mammary	inducible
PANC-1 Ecadherin EmGFP	CRL-1469MET™	Pancreatic carcinoma	Pancreas	inducible

LUCIFERASE-LABELED CELLS FOR IN VIVO AND IN VITRO STUDIES

ATCC has an ever-expanding collection of constitutively expressed luciferase-labeled cell lines, including CRISPR-genome edited lines with mutants of key oncogenes.

Designation	ATCC® No.	Disease	Tissue	Expression
4T1-Luc2	CRL-2539-LUC2™	Mimics human breast cancer Stage IV	Breast	Constitutive
A375-Luc2	CRL-1619-LUC2™	Malignant Melanoma	Skin	Constitutive
A-431-Luc2	CRL-1555-LUC2™	Epidermoid Carcinoma	Skin	Constitutive
A549-Luc2	CCL-185-LUC2™	Carcinoma	Lung	Constitutive
AGS-Luc2	CRL-1739-LUC2™	Gastric Adenocarcinoma	Stomach	Constitutive
B16-F10-Luc2	CRL-6475-LUC2™	Melanoma	Skin	Constitutive
B16-F1-Luc2	CRL-6323-LUC2™	Melanoma	Skin	Constitutive
EL4-Luc2	TIB-39-LUC2™	Lymphoma	Blood	Constitutive
EML4-ALK Fusion-A549 Isogenic-Luc2	CCL-185IG-LUC2™	Carcinoma	Lung	Constitutive
FaDu-Luc2	HTB-43-LUC2™	Squamous Cell Carcinoma	Pharynx	Constitutive
HCT 116-Luc2	CCL-247-LUC2™	Carcinoma Colorectal	Large intestine	Constitutive
HCT-15-Luc2	CCL-225-LUC2™	Adenocarcinoma Colorectal Dukes type C	Large intestine	Constitutive
HL-60-Luc2	CCL-240-LUC2™	Acute promyelocytic leukemia	Peripheral blood	Constitutive
HT-1080-Luc2	CCL-121-LUC2™	Fibrosarcoma	Connective tissue	Constitutive
IDH1 Mutant U-87 Isogenic-Luc2	HTB-14IG-LUC2™	Glioma	Brain	Constitutive
IDH2 mutant-TF-1 Isogenic-Luc2	CRL-2003IG-LUC2™	Erythroleukemia	Bone	Constitutive
K-562-luc2	CCL-243-LUC2™	Chronic Myelogenous Leukemia Cml	Bone	Constitutive
KRAS mutant-A375 Isogenic-Luc2	CRL-1619IG-1-LUC2™	Malignant Melanoma	Skin	Constitutive
LL/2-Luc2	CRL-1642-LUC2™	Lewis Lung Carcinoma	Lung	Constitutive
LNCaP clone FGC-Luc2	CRL-1740-LUC2™	Carcinoma	Prostate	Constitutive
MCF7-Luc2	HTB-22-LUC2™	Adenocarcinoma	Breast	Constitutive
NRAS-mutant-A375 Isogenic-Luc2	CRL-1619IG-2-LUC2™	Malignant Melanoma	Skin	Constitutive
PANC-1-Luc2	CRL-1469-LUC2™	Epithelioid Carcinoma	Pancreas	Constitutive
PC-3-Luc2	CRL-1435-LUC2™	Adenocarcinoma	Prostate	Constitutive
SW480-Luc2	CCL-228-LUC2™	Adenocarcinoma Colorectal Dukes type B	Large intestine	Constitutive
TF-1-Luc2	CRL-2003-LUC2™	Erythroleukemia	Bone	Constitutive
ThawReady™ THP-1 NF-kB-Luc2	TIB-202-NFkB-LUC2-AR™	Acute monocytic leukemia	Peripheral blood	Constitutive
ThawReady™ THP-1 NF-kB-Luc2; 3-Pack	TIB-202-NF-LUC2-AR3™	Acute monocytic leukemia	Peripheral blood	Constitutive
ThawReady™ THP-1 NF-kB-Luc2; 5-Pack	TIB-202-NF-LUC2-AR5™	Acute monocytic leukemia	Peripheral blood	Constitutive
ThawReady™ THP-1 NF-kB-Luc2; 10 pack	TIB-202-NF-LUC2-AR10™	Acute monocytic leukemia	Peripheral blood	Constitutive
U-2 OS-Luc2	HTB-96-LUC2™	Osteosarcoma	Bone	Constitutive
U-87 MG-Luc2	HTB-14-LUC2™	Glioma	Brain	Constitutive

 10801 University Boulevard
Manassas, Virginia 20110-2209

 703.365.2700

 703.365.2701

 sales@atcc.org

 www.atcc.org

RLC-042025-v01

©2025 American Type Culture Collection. The ATCC trademark and trade name, and any other trademarks listed in this publication are trademarks owned by the American Type Culture Collection unless indicated otherwise.

These products are for laboratory use only. Not for human or diagnostic use. ATCC products may not be resold, modified for resale, used to provide commercial services or to manufacture commercial products without prior ATCC written approval.